Aquestive TherapeuticsJanuary 30, 2025

FDA 483 - Aquestive Therapeutics - January 30, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Aquestive Therapeutics

Record Details

An FDA inspection of Aquestive Therapeutics in Portage, Indiana, revealed two significant observations. The firm failed to thoroughly investigate product complaints, specifically regarding white spots on SUBOXONE® sublingual film, and lacked adequate corrective and preventive actions. Additionally, the company did not have sufficient systems in place to comply with the Drug Supply Chain Security Act's verification requirements for suspect and illegitimate products.

Company: Aquestive Therapeutics
Inspection Date: January 30, 2025
Product Type: Drugs
Office: Detroit District Office
Person: Muna Algharibeh (Investigator)

Open in Dashboard

ID · 986d4495-7f77-47ff-acec-d2c38ff0c2ab